

## **The DIAMOND Trial Publications**

Citation: Butler J, Anker SD, Siddiqi TJ, et al. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. *Eur J Heart Fail*. 2022;24(1):230-238.

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300159/pdf/EJHF-24-230.pdf>

Citation: Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial [published online ahead of print, 2022 Jul 28]. *Eur Heart J*. 2022;ehac401.

Link: <https://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehac401/45179962/ehac401.pdf>

## **Guidelines**

### **2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure**

Citation: Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *J Card Fail*. 2022;28(5):e1-e167.

Link: <https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001063?download=true>

### **2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure**

Citation: McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Rev Esp Cardiol (Engl Ed)*. 2022;75(6):523.

Link: <https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab368/6358045>